Trials / Conditions / Extranodal NK/T-cell Lymphoma, Nasal Type

Extranodal NK/T-cell Lymphoma, Nasal Type

23 registered clinical trials studyying Extranodal NK/T-cell Lymphoma, Nasal Type — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Registry for People With T-cell Lymphoma NCT05978141	Memorial Sloan Kettering Cancer Center	—
Withdrawn	Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma NCT04639843	National Cancer Institute (NCI)	Phase 1
Recruiting	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas NCT05475925	Dren Bio	Phase 1 / Phase 2
Unknown	Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL NCT04676789	Sun Yat-sen University	Phase 2
Terminated	Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma NCT04602065	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1 / Phase 2
Active Not Recruiting	A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type NCT04414163	ImmuneOncia Therapeutics Inc.	Phase 2
Terminated	Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment o NCT04509466	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 1 / Phase 2
Unknown	Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma NCT04338282	Beijing Tongren Hospital	Phase 2
Unknown	GPED Regimen for Relapsed/Refractory or Advanced ENKTCL NCT04405375	Beijing Tongren Hospital	Phase 2
Unknown	SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma NCT03363555	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
Completed	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451	BeiGene	Phase 2
Completed	Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients NCT03079544	Rong Tao	—
Unknown	MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma NCT02631239	Ruijin Hospital	Phase 3
Completed	GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma NCT02733458	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	N/A
Unknown	CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma NCT02742727	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1 / Phase 2
Completed	MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Ly NCT02764281	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	N/A
Unknown	Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherap NCT02229682	Sun Yat-sen University	Phase 2
Unknown	GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma NCT01991158	Sun Yat-sen University	Phase 2
Unknown	Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma NCT01921790	Sun Yat-sen University	Phase 2
Completed	International Extranodal NK/T-cell Lymphoma Project NCT02386813	Samsung Medical Center	—
Unknown	Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma NCT01667302	Fudan University	Phase 2
Terminated	Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma NCT01667289	Fudan University	Phase 2
Completed	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma NCT00901147	Singapore General Hospital	Phase 2